ASX: MQG<\/a>) its analysts have put an outperform rating and $295.90 price target on its shares. This implies potential upside of 42% for investors over the next 12 months.<\/p>\nThis means that a $5,000 investment would turn into approximately $7,100 if Macquarie is on the money with its recommendation. It said:<\/p>\n
Despite downgrades to earnings, we view today’s price movement as an overreaction. Incorporating more conservative FY26 forecasts compared to guidance, we see the current valuation as undemanding (trading at P\/E ~20x with ~10% EPS growth). Outperform.<\/p>\n
Elsewhere, the team at Morgans is equally bullish on the investment opportunity here. The broker highlights that CSL is positioned to deliver “double-digit earnings growth over the medium term.” In light of this, it thinks its shares are undervalued at current levels.<\/p>\n
Morgans has a buy rating and $293.83 price target on its shares. Based on the current CSL share price, this suggests that upside of 41% is possible between now and this time next year.<\/p>\n
This would turn a $5,000 investment into approximately $7,050 in a year if the broker’s recommendation delivers the goods. It said:<\/p>\n
FY25 results were broadly in line, with double-digit underlying earnings growth, solid operating leverage and strong OCF. Behring was softer (+6%; hit by cUS$100m Medicare Part D reform), but margins gained on efficiencies (GPM +130bp, 51%; OPM +100bp, 42.2%), with Vifor showing resilience (+14%), while Seqirus was soft (-9%) on weak immunisation rates.<\/p>\n
As widely anticipated, CSL flagged a restructuring, streamlining R&D and commercial productivity, targeting US$500m pre-tax savings by YE28, but surprised with Seqirus demerger and multi-year share buyback (US$500m FY26). While investors have taken a glass half full approach, we believe the restructuring augments, not masks the underlying business, with streamlining operations and cost savings supporting double-digit earnings growth over the medium term. We adjust FY26-27 forecasts modestly, with our PT decreasing to A$293.83. BUY.<\/p>\n","protected":false},"excerpt":{"rendered":"Image source: Getty Images It has been a tough 12 months for the CSL Ltd (ASX: CSL) share…\n","protected":false},"author":2,"featured_media":143199,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[64,63,99,97275,7037,7038,7039,7040,10797],"class_list":["post-143198","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-au","tag-australia","tag-business","tag-category-blue-chip-shares","tag-partner-feeds-msn-9","tag-partner-feeds-newstex","tag-partner-feeds-sharesight","tag-partner-feeds-webull","tag-tickers_global-asx-csl"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/143198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=143198"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/143198\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/143199"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=143198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=143198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=143198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"A](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/09\/crystal-ball-new-16_9-1200x675.jpeg\")
<\/p>\n